While the whole world is rushing to come up with the vaccine for Coronavirus, all leading countries which are probably on the clinical trails stage declared that it would at least take three months for an approved formula. In the wake of which, India which right now is playing a crucial role in the global pharmaceutical community declared an interesting update on Tuesday.
Glenmark Pharmaceuticals, Mumbai-based company announced that it has initiated Phase 3 clinical trials on antiviral drug Favipiravir to check its efficacy on COVID-19 patients in India. Noted as the first company in the country to have received approval from Drug Controller General of India (DCGI), Glenmark in its official study claimed that over ten leading government and private hospitals are being enrolled for the study.
Reportedly, Glenmark has successfully developed the active pharma ingredient (API) whose commercialised formula will be marketed under the brand name FabiFlu in India. As per the approvals received, 150 enrolled patients with mild to moderate COVID-19 will be randomised in the study in a 1:1 ratio to Favipiravir with standard supportive care of total study duration will be a maximum of 28 days from randomisation.
